Elsevier

Immunology Letters

Volume 49, Issue 3, March 1996, Pages 143-147
Immunology Letters

Modulation of lipopolysaccharide-induced tumor necrosis factor-α and nitric oxide production by dopamine receptor agonists and antagonists in mice

https://doi.org/10.1016/0165-2478(96)02494-7Get rights and content

Abstract

The effects of various agonists and antagonists of dopamine D1 and D2 receptors on lipopolysaccharide (LPS)-induced tumor necrosis factor-α (TNF-α) and nitrix oxide (NO) production was investigated in mice. Pretreatment of animals with bromocryptine or quinpirole, agonists of dopamine D2 receptors caused a blunting of both the TNF-α and NO responses to LPS injected intraperitoneally. Sulpiride, an antagonist of dopamine D2 receptors, decreased the LPS-induced TNF-α plasma levels in a dose-dependent manner and inhibited the LPS-induced NO production by peritoneal macrophages. Bromocryptine or quinpirole blunted both the TNF-α and NO response to LPS. SCH-23390, an antagonist of dopamine D1 receptors did not alter LPS-induced TNF-α production, but inhibited LPS-induced NO production. These results indicate that while the D2 subtype of dopamine receptors is involved in the modulation of both LPS-induced TNF-α and NO production, dopamine D1 receptors only regulate the production of NO. Since several drugs possess effect on dopamine D2 receptors, the present observations may be of clinical relevance.

References (30)

  • RicciA. et al.

    J. Neuroimmunol.

    (1994)
  • Le FurG. et al.

    Life Sci.

    (1980)
  • NagyE. et al.

    Immunopharmacology

    (1983)
  • BokaG. et al.

    Neurosci. Lett.

    (1994)
  • GlauserM.P. et al.

    Lancet

    (1991)
  • FongY. et al.

    Clin. Immunol. Immunopathol.

    (1990)
  • BrosnanC.F. et al.

    J. Neuroimmunol.

    (1988)
  • ElenkovI.J. et al.

    J. Neuroimmunol.

    (1995)
  • SantambrgioL. et al.

    J. Neuroimmunol.

    (1993)
  • SternbergE.M. et al.

    J. Immunol.

    (1986)
  • SternbergE.M. et al.

    J. Immunol.

    (1987)
  • PierpaoliW. et al.

    Immunology

    (1978)
  • PierpaoliW. et al.

    J. Immunol.

    (1978)
  • KouassiE. et al.

    Immunopharm. Immunotechnol.

    (1987)
  • BoukhrisW. et al.

    J. Clin. Lab. Immunol.

    (1987)
  • Cited by (45)

    • Lipopolysaccharide/D-galactosamine-induced acute liver injury could be attenuated by dopamine receptor agonist rotigotine via regulating NF-κB signaling pathway

      2021, International Immunopharmacology
      Citation Excerpt :

      And Zhang’s research showed that DRD2 can control renal inflammation via inducing the levels of p-Akt and p-NFκBp65 and the expression of TNF-α and IL-6 [20]. Studies showed that DA can reduce the secretion of TNF-α and IL-1β in LPS-treated macrophages and microglial cells [21,22]. It has also been shown that the DA receptor agonist pramipexole can inhibit the expression of inflammatory cytokines, such as IL-17, IL-1β and TNF-α in peripheral lymphoid tissues [23].

    • Targeting of G-protein coupled receptors in sepsis

      2020, Pharmacology and Therapeutics
      Citation Excerpt :

      Stimulation of β-adrenoceptors leads to an increase in the intracellular concentration of cAMP in immune cells. Consequently, increase in intracellular cAMP concentration by phosphodiesterase inhibitors and dopamine receptor agonists has been demonstrated to have a similar impact on cytokine secretion from immune cells (Hasko et al., 1996; Hasko, Nemeth, Vizi, Salzman, & Szabo, 1998). Stimulation of β-adrenoceptors also has an impact on the adaptive immune response by inhibiting the release of IFNγ and stimulating the release of IL-10; this inhibits the formation of TH1 cells and promotes differentiation into TH2 cells (Panina-Bordignon et al., 1997).

    • The role of neutrophils in neuro-immune modulation

      2020, Pharmacological Research
      Citation Excerpt :

      This down-regulation is mediated by sunlight stimulation of β3ARs [79]. Another catecholamine that showed a great anti-inflammatory potential is dopamine [80,81]. There are two families of dopaminergic receptors: D1-type (including D1 and D5 subtypes) and D2-type (D2, D3, and D4 subtypes) [82].

    • Dopamine alleviated acute liver injury induced by lipopolysaccharide/D-galactosamine in mice

      2018, International Immunopharmacology
      Citation Excerpt :

      These findings suggest that DA might have anti-inflammatory effects in LPS/D-Gal-exposed mice. In agreement with our findings, DA inhibited LPS-induced production of TNF-α and NO in macrophages or glial cells [14, 16], DA also inhibited the elevation of TNF-α in neurodegenerative diseases such as Parkinson's disease [30–33]. Thus, the anti-inflammatory properties of DA might be responsible for, at least partially, its beneficial effects on LPS/D-Gal-induced acute liver injury.

    • Paracrine Regulation of Renal Function by Dopamine

      2013, Seldin and Geibisch's The Kidney
    • Paracrine Regulation of Renal Function by Dopamine

      2012, Seldin and Giebisch's The Kidney: Physiology and Pathophysiology
    View all citing articles on Scopus
    View full text